Acute myeloid leukaemia after treatment with (90)Y-ibritumomab tiuxetan for follicular lymphoma.

MLA

Focosi D, et al. “Acute Myeloid Leukaemia after Treatment with (90)Y-Ibritumomab Tiuxetan for Follicular Lymphoma.” Hematological Oncology, vol. 26, no. 3, Sept. 2008, pp. 179–81. EBSCOhost, https://doi.org/10.1002/hon.849.

APA

Focosi D, Cecconi N, Boni G, Orciuolo E, Galimberti S, Petrini M, Focosi, D., Cecconi, N., Boni, G., Orciuolo, E., Galimberti, S., & Petrini, M. (2008). Acute myeloid leukaemia after treatment with (90)Y-ibritumomab tiuxetan for follicular lymphoma. Hematological Oncology, 26(3), 179–181. https://doi.org/10.1002/hon.849

Chicago

Focosi D, Cecconi N, Boni G, Orciuolo E, Galimberti S, Petrini M, Daniele Focosi, et al. 2008. “Acute Myeloid Leukaemia after Treatment with (90)Y-Ibritumomab Tiuxetan for Follicular Lymphoma.” Hematological Oncology 26 (3): 179–81. doi:10.1002/hon.849.